Table 7 Microbiological and clinical information of Cefditoren-resistant isolates

BA 356 E. coli

1

S

S

I

R

S

S

S

S

S

S

S

S

S

S

S

S

S

S

TEM-1 hyperproduction

NA

BA 425 E. coli

1

S

S

S

R

S

S

S

S

S

S

S

S

S

S

S

S

S

R

TEM-1 + SXT^R

75ys female AUC, doxycycline in the last 3mos

BC 165 E. coli

1

S

S

R

R

S

S

S

R

S

S

S

S

S

S

S

S

S

S

TEM-1 hyperproduction

25ys female UTI, Hx of UTI in the last 2wks

BC 211 E. coli

1

R

S

I

R

S

S

S

R

S

S

S

S

R

S

S

S

S

R

TEM-1 hyperproduction + SXT^R + cross resistance to all fluoroquinolones

81ys female AB with diabetes mellitus and nephrolithiasis, Hx of UTI in the last 2ks and 3 mos, use of CIP in the last 3mos

BTH 486 E. coli

1

S

S

I

R

S

S

S

S

S

S

S

S

S

S

S

S

S

R

TEM-1 hyperproduction + SXT^R

NA

BM 538 E. coli

1

S

S

I

R

S

S

S

R

S

S

S

S

S

S

S

S

S

S

TEM-1 hyperproduction

NA

PER 41ii E. coli

1

S

S

S

R

S

S

S

S

S

S

S

S

S

S

S

S

S

S

TEM-1

45ys male AB, Hx of UTI in the last year

BTH 229 Klebsiella spp

2

S

S

S

R

S

S

S

S

S

S

S

S

S

S

I

S

S

R

SHV-1 natural + FT^R + SXT^R

NA

BP 129 E. coli

2

-

S

R

R

S

S

I

R

R

S

S

S

S

S

R

S

S

S

TEM-1 hyperproduction + FT^R + FOS^R

NA

P 72 Klebsiella spp

2

R

S

S

R

S

S

S

S

S

S

S

S

R

S

R

S

S

R

SHV-1 + FT^R + SXT^R + cross resistance to all fluoroquinolones

80ys female AB with folley catheter, Hx of UTI in the last 2wks and 3mos, use of cefaclor and TZP in the last 3 months

BK 319 E. coli

4

R

S

I

R

S

S

S

S

S

S

S

S

R

S

S

S

S

R

TEM-1 hyperproduction + SXT^R + cross resistance to all fluoroquinolones

18ys female AUC, Hx of UTI in the last 3mos

BA 569 E. coli

16

S

S

S

R

R

S

R

R

S

S

S

S

S

S

S

S

S

R

ESBL CTX-type + SXT^R

NA

BTH 470 E. coli

32

S

S

S

R

R

S

R

R

S

S

S

S

R

S

S

S

S

S

ESBL CTX-type + Resistance quinolones Nal^R

40ys female AUC, Hx of UTI in the last year

BM 593 E. coli

32

S

S

S

R

R

S

R

R

S

S

S

S

R

S

S

S

S

R

ESBL CTX-type + SXT^R + Resistance quinolones Nal^R

NA

BA 524 Klebsiella spp

64

R

S

S

R

R

R

R

R

S

S

S

R

R

S

S

S

S

S

ESBL + Mecilinam^R + Cross resistance to all fluoroquinolones

NA

BM 463 P. mirabilis

64

S

S

R

R

S

S

S

R

S

S

S

S

S

S

R

S

S

S

AmpC plasmidic + natural FT^R

56ys female, fever-frequency-dysuria-pyuria, use of cefaclor in the last 3 mos

BM 465 P. mirabilis

64

S

S

R

R

S

S

S

R

S

S

S

S

S

S

R

S

S

S

AmpC plasmidic + natural FT^R

36ys female AUC, history of UTI in the last 3mos and use of CIP

BM 466 P. mirabilis

64

S

S

R

R

S

S

S

R

S

S

S

S

S

S

R

S

S

S

AmpC plasmidic + natural FT^R

NA

BA 315 E. coli

128

S

S

I

R

R

S

R

R

S

S

S

S

R

S

S

S

I

I

ESBL CTX-type + SXT^R + Resistance quinolones Nal^R

80ys female AB with folley catheter, Hx of UTI in the last 3mos, use of SXT and TZP in the last 3mos, recent hospital admission

GEM 167 E. coli

128

S

S

I

R

R

S

R

R

S

S

S

S

S

S

S

S

S

R

ESBL CTX-type + SXT^R

NA

GEM 250 E. coli

128

R

S

S

R

R

S

R

R

S

S

S

S

R

S

S

S

S

R

ESBL CTX-type + SXT^R + Cross resistance to all fluoroquinolones

68ys female, fever-pyuria, diabetes mellitus and nephrolithiasis, Hx of UTI in the last 2wks and use of CIP, Hx of recent hospital admission

GEM 315 E. coli

128

S

R

S

R

R

R

R

R

R

S

S

R

S

S

R

I

S

R

ESBL + SXT^R + FT^R + FOS^R

NA

TZ 250 E. coli

128

R

R

R

R

R

R

R

R

S

R

R

R

R

R

R

R

R

R

MBL (XDR) + Cross resistance to all fluoroquinolones

NA